| Nov 13 |
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
|
| Nov 12 |
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
|
| Nov 8 |
Eupraxia Pharmaceuticals reports Q3 results
|
| Nov 7 |
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
|
| Oct 31 |
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
|
| Oct 10 |
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
|
| Oct 2 |
Eupraxia Pharmaceuticals Strengthens Senior Management Team
|
| Sep 19 |
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
|
| Sep 11 |
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
|
| Sep 4 |
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
